ClinicalTrials.gg
CompletedNCT04644809Updated Aug 10, 2022

A Study of LY3561774 in Participants With Dyslipidemia

A Phase 1 interventional study of LY3561774 and Placebo in Dyslipidemias, sponsored by Eli Lilly and Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2022, 4 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Dyslipidemias by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Eli Lilly and Company.

Enrollment
7th of 10
74 · median 133
Started
2020
the only one that year
Phase 1
5 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Dyslipidemias by Eli Lilly and Company, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 1, and was the 7th registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 10 studies in Dyslipidemias by Eli Lilly and Company is open now. The open studies under Dyslipidemias, anywhere →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Dyslipidemias by Eli Lilly and Company as a file.
02

Study summary

This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Parts A and B, have a fasting triglyceride (TG) level greater than or equal to (≥) 150 milligram/deciliter (mg/dL) and less than 500 mg/dL, as well as low density lipoprotein cholesterol (LDL-C) level greater than or equal to (≥) 70 mg/dL
  • For Part C, participants should be first-generation Japanese origin.
  • Have a (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²)
  • Male participants must agree to adhere to restrictions and female participants must not be able to get pregnant

Exclusion criteria

Exclusion Criteria:

  • Have taken any prescription medications that are for lowering serum TGs within the past 2 months (use of statins is allowed if the dose has been stable for 8 weeks)
  • Have Type 1 diabetes
  • Are currently participating in or completed a clinical trial within the last 30 days
  • Are heavy alcohol drinkers or heavy cigarette smokers
  • Have donated blood of more than 500 millilitres (mL) in the last 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    LY3561774 (Part A)

    Single ascending doses of LY3561774 administered subcutaneously (SC).

    Drug: LY3561774

  • Experimental
    LY3561774 (Part B)

    Repeat doses of LY3561774 administered SC.

    Drug: LY3561774

  • Experimental
    LY3561774 (Part C)

    Single doses of LY3561774 administered SC in Japanese Participants.

    Drug: LY3561774

  • Placebo comparator
    Placebo (Part A, B & C)

    Placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC.

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Week 53

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3561774

    PK: AUC\[0-tlast\] of LY3561774

    Time frame: Predose through Day 8

  2. PK: Maximum Observed Drug Concentration (Cmax) of LY3561774

    PK: Cmax of LY3561774

    Time frame: Predose through Day 8

  3. PK: Time of Maximum Observed Concentration (Tmax) of LY3561774

    PK: Tmax of LY3561774

    Time frame: Predose through Day 8

  4. PD: Change From Baseline in Fasting Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C)

    PD: Change From Baseline in Fasting TG and LDL-C

    Time frame: Predose through Week 53

07

Study locations

5 sites
  • Altasciences Clinical Los Angeles, Inc
    Cypress, California 90630, United States
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2022, 17 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 17 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2020
First posted
Nov 25, 2020
StartActual
Nov 30, 2020
Primary completionActual
May 17, 2022
CompletionActual
May 17, 2022
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04644809
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Nov 30, 2020
Primary completion
May 17, 2022
Completion
May 17, 2022
Last update
Aug 10, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solbinsiran

Start the discussion